Newsroom

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This app...

SAN FRANCISCO--(BUSINESS WIRE)--Marquee customer wins, analyst recognition, and platform innovation underscore Opsin's leadership in governance for autonomous enterprise agents....

ELMORE CITY, Okla.--(BUSINESS WIRE)--Old Glory Bank has announced the recipient of its 2026 Merit Scholarship, recognizing achievement in academic excellence, leadership, and service....

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend...

NEWTON, Mass.--(BUSINESS WIRE)--Office Properties Income Trust (“OPI” or the “Company”) today announced that it has successfully completed its financial restructuring and has emerged from Chapter 11. OPI achieved its objectives to strengthen its balance sheet, reduce debt, and position the Company for long-term operational stability. Pursuant to OPI’s Chapter 11 Plan of Reorganization confirmed by the U.S. Bankruptcy Court for the Southern District of Texas on April 22, 2026, OPI entered into t...

NEWCASTLE & HOUSTON--(BUSINESS WIRE)--TechnipFMC (NYSE: FTI) will host its second-quarter 2026 earnings conference call on Thursday, July 30, 2026, at 1:30 p.m. London time (8:30 a.m. New York time). A press release announcing the results will be issued prior to the call at approximately 11:45 a.m. London time (6:45 a.m. New York time). The event will be webcast live and can be accessed via the Investor Relations website, or by registering here. A replay of the webcast will be available on the...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the study’s dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared to placebo on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week eight in adults with NT2 (n=...

NEW YORK--(BUSINESS WIRE)--Urban Edge Properties Invites You to Join Its Second Quarter 2026 Earnings Conference Call...

DUBLIN--(BUSINESS WIRE)--ICON Schedules First Quarter 2026 Earnings Conference Call...

WHEATON, Ill.--(BUSINESS WIRE)--First Trust Advisors L.P. ("FTA") announces the declaration of the Monthly distribution for FT Vest U.S. Equity Buffer & Premium Income ETF - June, a series of First Trust Exchange-Traded Fund VIII. The following dates apply to today's distribution declaration: Expected Ex-Dividend Date: June 18, 2026 Record Date: June 18, 2026 Payable Date: June 22, 2026 Ticker Exchange Fund Name Frequency Ordinary Income Per Share Amount   ACTIVELY MANAGED EXCHANGE-TRADED F...